Evidence map›Paper›PMID 38818906›Full record

ArticleCurrent cancer drug targets2025

Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis

Xing Ma, Yifan Gan, Zhongchao Mai, Yanan Song, Miao Zhang, Wei Xia

Abstract read
PubMed Publisher
In one paragraph

Article in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xing MaDepartment of Nuclear Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai , China.
Yifan GanCentral Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhongchao MaiDepartment of Nuclear Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai , China.
Yanan SongCentral Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Miao ZhangCentral Laboratory, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wei XiaDepartment of Nuclear Medicine, Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai , China.

Funding

chron-ic disease management project of Traditional Chinese Medicine Health Service Center of Shanghai University of Traditional Chinese Medicine ZYJKFW201811004excellent subject leader training project of the three-year action plan of the Shanghai public health system GWV-10.2-XD15key discipline construction project of the three-year action plan of the Shanghai public health system GWV-10.1-XK9leading personnel training plan of health system of Pu-dong New Area, Shanghai PWRI2019-03Shanghai Science and Technology Committee Foundation 22ZR1447900
6 · The paper itself

Abstract

backgroundCisplatin (DDP) is a commonly used chemotherapy agent. However, its resistance to the drug is a major challenge in its clinical application. Earlier research has suggested a connection between HEATR1 and chemoresistance in cancer. However, additional investigation is needed to better understand its involvement in resistance to DDP. In this study, we aimed to determine the regulatory effect of HEATR1 on the resistance of cisplatin in NSCLC.

methodsWe collected specimens of both DDP-resistant and non-resistant NSCLC to examine the expression of HEATR1. Additionally, we established cisplatin-resistant cells of NSCLC using the A549 cell line. Cell ability was examined by CCK-8 assay. Cell apoptosis and lipid ROS were examined by flow cytometry. The expressions of HEATR1, p53, SAT1, and ALOX15 were determined by qRT-PCR and Western blot. The tumor xenograft experiment was conducted to assess the impact of silencing HEATR1 on cisplatin resistance

resultsThe expression levels of HEATR1 were found to be significantly elevated in DDP-resistant tissues and cells of NSCLC as compared to non-resistant counterparts. Conversely, the expression levels of p53, SAT1, and ALOX15 were observed to be reduced in DDP-resistant cells. Through the inhibition of HEATR1, the proliferation of DDP-resistant cells was significantly suppressed, while the generation of lipid ROS was enhanced. This effect was achieved by activating ferroptosis and the p53/SAT1/ALOX15 pathway, as demonstrated both

conclusionFinally, the findings revealed that HEATR1 silencing reduced DDP resistance in NSCLC by inducing ferroptosis via the p53/SAT1/ALOX15 axis. HEATR1 might become a potential target for overcoming DDP resistance in NSCLC treatment.

Indexed as

Carcinoma, Non-Small-Cell LungCisplatinDrug Resistance, NeoplasmFerroptosisLung NeoplasmsTranscription FactorsTumor Suppressor Protein p53AnimalsAntineoplastic AgentsFemaleHumansMaleMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53ALOX15 axis.DDP resistanceferroptosisHEATR1NSCLCp53SAT1

Identifiers

PMID38818906

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.